about dan watson

Since 2010 I have been focused on researching and investing in Pharmaceutical, Biotech, and Medical Technology companies. I focus on companies that are developing medicines or have developed medicines for diabetes, Alzheimer’s, cancer, hepatitis, Crohn’s disease, and others. I have been very successful with this investment strategy since 2009. My first successful healthcare/biotech investment was on March 12th, 2009 when Roche® purchased a biotechnology company that I held stock in - Genentech®. Roche’s purchase of Genentech for $46.8 Billion was the motivation to review the entire healthcare sector.  Highlighted below are companies that I have or have had long positions in since 2010 and I will occasionally trade in and out these companies.  From my perspective the biotech sector has been on a bull run since 2009. On February 7th, 2018, 2 days after the ^VIX inspired high volatility crash/correction on February 5th and 6th of 2018, I again went “all in” on the Healthcare sector. More importantly the cancer death rate in the U.S. fell 13% from 2004 to 2013 according to those who track such information.

Please be advised that I am not a financial adviser/investment adviser, and I have no business relationship with any of the company’s who are mentioned below. I have worked for Unilever®, Grey Advertising®, Hasbro®, Toys R Us® and other companies prior to 2010.   I consider myself, insightful regarding trends and products, market timing, identifying long-term value situations, long-term brand development, and identifying technologies and products that will be highly profitable.  I do not “blog” often, as I spend more time processing information then communicating data.  I have been following many Seeking Alpha writers as a member since 2012.  I also gain information/data/charts from many other sources. And have many Google Alerts and Company alerts directly sent to me on diseases, and product tests involving new medicines.  These are extraordinary times for investing and processing new products and ventures and is not limited to the healthcare sector.  However, the amounts of money being devoted to new medical technologies and new medicines is remarkable. Before February 5th, 2018 I was a passive investor, no longer. I am now an active supporter of all the healthcare, medical, and biotech companies that I hold stock in.  Please be advised that this is not investment advise, these are my investments.  Thank you for visiting seeking biotech alpha and please feel free to send me comments/feedback/questions. 
(CELG), (ABBV), (AMGN), (BMY), (JNJ), (ABT), (LLY), (MRK), (PFE), (NVS), (NVO), (BIIB), (MDT), (ABMD), (ISRG), (AZN), (RHHBY), (GILD), (REGN), (GERN), (BGNE), (SGMO), (BMRN), (VRTX), (ILMN), (A), (PKI), (INCY), (TMO)

Thank you for visiting www.seekingbiotechalpha.com and 


Roche Agrees to Buy Genentech for $46.8 Billion - The New York Times

danwatson.com

dan watson @ Linkedin

about dan watson

comments and blogs posted on seeking alpha  

dan watson @ Seeking Alpha

  "The Little Toy Company That Could" 

LARAMI 

dan watson @ larami

 dan watson's real time 24/7 portfolio - seeking biotech alpha  @ GuruFocus

seeking biotech alpha portfolio 24/7 @ GURUFOCUS

From prison to park: Camden's Cooper's Poynt Phaedra Trethan

A Prison Falls, a Playground Rises in North Camden By Matt Skoufalos | June 5, 2017

 Overhauling the site was a project that took decades and millions of dollars. The Delaware River Port Authority allocated $8 million for demolition of the prison, and the New Jersey Economic Development Authority (EDA) supplemented that with $5 million in planning and infrastructure grants. 

 


The Wells Fargo Regional Foundation kicked in $750,000 for a neighborhood planning grant, and the William Penn Foundation added another quarter-million dollars for the bikeway improvements. 


 

There are plans to construct a mixed-use commercial-residential development on the surrounding property at Cooper’s Poynt, but the EDA still hasn’t found qualified developers to take on the project.

Maureen Hassett, EDA senior vice president of governance, communications, and strategic initiatives, said the agency is evaluating options for the land, which is still owned by the New Jersey Department of Corrections. 


 

Rodney Sadler, Executive Director of the Save Our Waterfront neighborhood coalition, recollected the years of work that went into salvaging the property, from opposing construction of the prison to the day it was leveled.

“It made a difference,” Sadler said. “It made it possible.” 


 A Prison Falls, a Playground Rises in North Camden 


Cooper’s Poynt Playground. Credit: Matt Skoufalos.

“There needs to be that other connection,” Sadler said. “It has to start somewhere.”

 

Cooper's Poynt Park, 801-811 Delaware Ave, Camden, NJ 08102

A Prison Falls, a Playground Rises in North Camden By Matt Skoufalos June 5, 2017 NJPEN.com

The 10 Hottest Bioincubators in Europe

"We are building the Next Generation of Digital Media for Biotech" Philip, Joachim and Labiotech.eu

 A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups. 


 Sectors: Pharmaceutical and Agricultural. 


 Sectors: Biotechnology 


 Sectors: Biotherapies, Genetics, Biotechnology 


 Sectors:  Immuno-Oncology 


 Sectors: Life Sciences 


 Sectors: Agrifood, Bioeconomy and Life Sciences 


 Sectors: Biotechnology and Health 


 Sectors:  Healthcare and Pharmaceuticals